TCGA-B6-A0IE-01A-11R-A034-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 66
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.410
- ESTROGEN_RESPONSE_EARLY+0.340
- PANCREAS_BETA_CELLS+0.340
- ESTROGEN_RESPONSE_LATE+0.320
- MYC_TARGETS_V1+0.310
- DNA_REPAIR+0.240
- OXIDATIVE_PHOSPHORYLATION+0.230
- UNFOLDED_PROTEIN_RESPONSE+0.200
- FATTY_ACID_METABOLISM+0.170
- PEROXISOME+0.170
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.490
- INFLAMMATORY_RESPONSE-0.480
- IL6_JAK_STAT3_SIGNALING-0.470
- INTERFERON_GAMMA_RESPONSE-0.470
- TNFA_SIGNALING_VIA_NFKB-0.470
- HEDGEHOG_SIGNALING-0.430
- ALLOGRAFT_REJECTION-0.400
- MITOTIC_SPINDLE-0.380
- KRAS_SIGNALING_UP-0.350
- UV_RESPONSE_DN-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-OL-A66O-01A-11R-A31O-07 | — | B | 0.870 |
| 2 | SRR12202489 | — | — | 0.851 |
| 3 | TCGA-37-5819-01A-01R-1635-07 | — | cohortA3 | 0.844 |
| 4 | TCGA-5T-A9QA-01A-11R-A41B-07 | — | B | 0.842 |
| 5 | 85d43afd-9aac-48ca-a9c4-00357b7207e1 | — | — | 0.838 |
| 6 | TCGA-JL-A3YX-01A-11R-A22U-07 | — | B | 0.836 |
| 7 | 20120289.LumB | — | B | 0.836 |
| 8 | TCGA-AO-A0J7-01A-11R-A034-07 | — | B | 0.833 |
| 9 | TCGA-B6-A0IB-01A-11R-A034-07 | — | B | 0.833 |
| 10 | a9e8b311-dfde-4c34-80a2-5e64f94c596b | — | — | 0.829 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.410 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.340 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.340 | Cobimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.320 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.310 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.240 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.230 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.200 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.170 | Inavolisib | — uncovered |
| PEROXISOME | 0.170 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.160 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.150 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.080 | Inavolisib | — uncovered |
| MYOGENESIS | 0.050 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.040 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.040 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.020 | Inavolisib | — uncovered |